MedTrace Logo

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

NCT05695859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-03-01

No results posted yet for this study

Summary

An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies.

Conditions

  • Breast Cancer Female

Interventions

DRUG

99mTc-DARPinG3 SPECT/CT

One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    lead OTHER

Principal Investigators

  • Vladimir Chernov, MD · Tomsk NRMC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695859 on ClinicalTrials.gov